All peptides
CardiovascularFDA Approved

Carperitide (h-ANP)

Intravenous
Written by Peptide Association Editorial TeamMedically reviewed by Ian Justl Ellis, MD, CPTLast reviewed Editorial policy

Overview

Carperitide is a recombinant form of human atrial natriuretic peptide consisting of 28 amino acids. It activates guanylyl cyclase A receptors, increasing intracellular cyclic GMP to promote vasodilation, natriuresis, and diuresis.

Mechanism of Action

The peptide reduces cardiac preload and afterload while inhibiting the renin-angiotensin-aldosterone system, providing therapeutic benefit in acute heart failure.

Research Summary & Key Findings

Carperitide received approval in Japan in 1995 for treatment of acute heart failure. Clinical trials in Japanese populations demonstrated hemodynamic improvement and symptom relief in acute decompensated heart failure, though the peptide has not been approved by regulatory agencies outside Japan.

Clinical Status

FDA Approved

Carperitide (h-ANP) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.

Administration Routes

Intravenous

References

Primary literature

Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.

Related Peptides in Cardiovascular

Start Your Consultation

Get an AI-proposed Carperitide (h-ANP) protocol reviewed by a physician in our network.

Start Your Consultation

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Carperitide (h-ANP).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.